A Review of Aflibercept Treatment for Macular Disease

Aflibercept is a fully human recombinant fusion protein that includes the second domain of human VEGF receptor 1 and the third domain of human VEGF receptor 2. Despite the important role played by VEGF in maintaining the physiological condition of the retina under normal conditions, dysregulation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Anguita, Rodrigo, Tasiopoulou, Anastasia, Shahid, Syed, Roth, Janice, Sim, Sing Yue, Patel, Praveen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319283/
https://www.ncbi.nlm.nih.gov/pubmed/34120317
http://dx.doi.org/10.1007/s40123-021-00354-1
_version_ 1783730413394460672
author Anguita, Rodrigo
Tasiopoulou, Anastasia
Shahid, Syed
Roth, Janice
Sim, Sing Yue
Patel, Praveen J.
author_facet Anguita, Rodrigo
Tasiopoulou, Anastasia
Shahid, Syed
Roth, Janice
Sim, Sing Yue
Patel, Praveen J.
author_sort Anguita, Rodrigo
collection PubMed
description Aflibercept is a fully human recombinant fusion protein that includes the second domain of human VEGF receptor 1 and the third domain of human VEGF receptor 2. Despite the important role played by VEGF in maintaining the physiological condition of the retina under normal conditions, dysregulation of VEGF can result in pathological alterations including hyperpermeability of the retinal capillaries and migration and proliferation of retinal endothelial cells. Over the years, a number of studies have evaluated the use of intravitreal aflibercept in different retinal diseases. In this review, we aim to summarize the scientific evidence and recommendations for use of intravitreal aflibercept in neovascular age-related macular degeneration, diabetic macular oedema, macular oedema associated with retinal vein occlusion, and myopic choroidal neovascularization.
format Online
Article
Text
id pubmed-8319283
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-83192832021-08-02 A Review of Aflibercept Treatment for Macular Disease Anguita, Rodrigo Tasiopoulou, Anastasia Shahid, Syed Roth, Janice Sim, Sing Yue Patel, Praveen J. Ophthalmol Ther Review Aflibercept is a fully human recombinant fusion protein that includes the second domain of human VEGF receptor 1 and the third domain of human VEGF receptor 2. Despite the important role played by VEGF in maintaining the physiological condition of the retina under normal conditions, dysregulation of VEGF can result in pathological alterations including hyperpermeability of the retinal capillaries and migration and proliferation of retinal endothelial cells. Over the years, a number of studies have evaluated the use of intravitreal aflibercept in different retinal diseases. In this review, we aim to summarize the scientific evidence and recommendations for use of intravitreal aflibercept in neovascular age-related macular degeneration, diabetic macular oedema, macular oedema associated with retinal vein occlusion, and myopic choroidal neovascularization. Springer Healthcare 2021-06-13 2021-09 /pmc/articles/PMC8319283/ /pubmed/34120317 http://dx.doi.org/10.1007/s40123-021-00354-1 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Anguita, Rodrigo
Tasiopoulou, Anastasia
Shahid, Syed
Roth, Janice
Sim, Sing Yue
Patel, Praveen J.
A Review of Aflibercept Treatment for Macular Disease
title A Review of Aflibercept Treatment for Macular Disease
title_full A Review of Aflibercept Treatment for Macular Disease
title_fullStr A Review of Aflibercept Treatment for Macular Disease
title_full_unstemmed A Review of Aflibercept Treatment for Macular Disease
title_short A Review of Aflibercept Treatment for Macular Disease
title_sort review of aflibercept treatment for macular disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319283/
https://www.ncbi.nlm.nih.gov/pubmed/34120317
http://dx.doi.org/10.1007/s40123-021-00354-1
work_keys_str_mv AT anguitarodrigo areviewofaflibercepttreatmentformaculardisease
AT tasiopoulouanastasia areviewofaflibercepttreatmentformaculardisease
AT shahidsyed areviewofaflibercepttreatmentformaculardisease
AT rothjanice areviewofaflibercepttreatmentformaculardisease
AT simsingyue areviewofaflibercepttreatmentformaculardisease
AT patelpraveenj areviewofaflibercepttreatmentformaculardisease
AT anguitarodrigo reviewofaflibercepttreatmentformaculardisease
AT tasiopoulouanastasia reviewofaflibercepttreatmentformaculardisease
AT shahidsyed reviewofaflibercepttreatmentformaculardisease
AT rothjanice reviewofaflibercepttreatmentformaculardisease
AT simsingyue reviewofaflibercepttreatmentformaculardisease
AT patelpraveenj reviewofaflibercepttreatmentformaculardisease

Ejemplares similares